


**Version of Claims with Markings (Amendments highlighted in bold, language to be added underlined, language to be deleted stricken through.)**

1. (Amended) A compound of the formula:



or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar<sup>1</sup> is ~~an aryl or heteroaryl group;~~

Ar<sup>2</sup> is ~~an aryl, heteroaryl or aralkyl group or Ar<sup>1</sup> and Ar<sup>2</sup> together form a fluorene, substituted fluorene or fluorenone group with the proviso that Ar<sup>3</sup> must be arylene;~~



Ar<sup>3</sup> is ~~an arylene or heteroarylene group;~~


said Ar<sup>1</sup>, ~~Ar<sup>2</sup>~~ and Ar<sup>3</sup> ~~groups possessing~~ possesses 0 to 3 substituents independently selected from the group consisting of -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, halo, -CN, -(C<sub>1</sub>-C<sub>6</sub>)alkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, -CONH<sub>2</sub>, -CONH(C<sub>1</sub>-C<sub>6</sub>)alkyl, -CON(C<sub>1</sub>-C<sub>6</sub>)alkyl (C<sub>1</sub>-C<sub>6</sub>)alkyl, -NH<sub>2</sub>, -NH C(O)(C<sub>1</sub>-C<sub>6</sub>)alkyl, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, -S(C<sub>1</sub>-C<sub>6</sub>)alkyl, -SO(C<sub>1</sub>-C<sub>6</sub>)alkyl, -SO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, methylenedioxy and NO<sub>2</sub>;

X is O, ~~S or N-CN;~~

Y is a single bond or a -(C<sub>1</sub>-C<sub>4</sub>)alkylene- group;

R<sup>1</sup> is ~~[thiazole, aryl or heteroaryl; or]~~





$R^1$  is  $-N(R^5)_2$ ,  $-NHC(O)(C_2-C_3)\text{alkylene}-N(R^5)_2$ ,  $-C(O)NH(C_2-C_3)\text{alkylene}$ ,  $-N(R^5)_2-C(O)N(Me)(C_2-C_3)\text{alkylene}-N(R^5)_2$ ,  $-C(OH)(C_4-C_2)\text{alkylene}-N(R^5)_2$ ,  $-N(Me)(C_2-C_3)\text{alkylene}-N(R^5)_2$ ,  $-NH(C_2-C_3)\text{alkylene}-C(O)R^5$ ,  $-N(Me)(C_2-C_3)\text{alkylene}-N(Me)SO_2(R^5)$  or  $-N(Me)(C_2-C_3)\text{alkylene}-C(O)N(R^5)_2$ ;

$R^2$  is H or  $-(C_1-C_6)\text{alkyl}$ ;

$R^3$  is independently H, or nonsubstituted or halosubstituted  $-(C_1-C_6)alkyl$ ,  $-(C_3-C_7)cycloalkyl$ ,  $-(C_3-C_7)cycloalkyl(C_1-C_6)alkyl$ ,  $-(C_1-C_6)alkoxy$ ,  $-(C_1-C_6)alkoxy(C_1-C_6)alkylene$ , aryl, -aralkyl or -heteroaralkyl; or

$R^4$  is H, nonsubstituted or halosubstituted  $-(C_1-C_6)alkyl$ ,  $-NH(C_1-C_6)alkyl$ ,  $-NHaryl$ , aryl; or alkoxy or hydroxy substituted alkyl, and

$R^5$  is independently H, or nonsubstituted or halosubstituted  $-(C_1-C_6)alkyl$ ,  $-(C_3-C_7)cycloalkyl$ ,  $-(C_3-C_7)cycloalkyl(C_1-C_6)alkyl$ , aryl, -aralkyl, -heteroaralkyl,  $-(C_1-C_6)alkoxy$  or  $(C_1-C_6)alkylene(C_1-C_6)alkoxy$ .


3. (Amended) A compound as defined in Claim 1;

or a pharmaceutically acceptable addition salt and or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

$Ar^1$  and  $Ar^2$  are independently phenyl or pyridyl,

$Ar^3$  is 1, 4-arylene,

$R^1$  is  in which  $R^3$  is  $-(C_1-C_6)alkyl$ ,  $-(C_3-C_7)cycloalkylmethyl$ ,  $(C_1-C_6)alkoxy-$  or  $(C_1-C_6)alkoxy(C_1-C_6)alkylene-$ ,

$R^2$  is H,

X is O; and

Y is a single bond or  $-(C_1-C_3)alkylene$ .

~~4. (Canceled) A compound as defined in Claim 1~~

~~Or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;~~

—wherein

~~Ar<sup>1</sup> and Ar<sup>2</sup> are independently phenyl or pyridyl,~~

~~Ar<sup>3</sup> is 1,4-arylene,~~

~~R<sup>1</sup> is N(R<sup>5</sup>)<sub>2</sub> or C(O)NH(C<sub>2</sub>-C<sub>3</sub>)alkylene N(R<sup>5</sup>)<sub>2</sub> in which each R<sup>5</sup> is independently H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, ar(C<sub>1</sub>-C<sub>6</sub>)alkyl, heteroaryl, heteroarylalkyl, halo-substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl,~~

X is O; and

~~Y is (C<sub>2</sub>-C<sub>3</sub>)alkylene.~~

5. (Amended) A compound as defined in Claim 1


or a pharmaceutically acceptable addition salt and/or hydrate thereof, or where applicable, a geometric or optical isomer or racemic mixture thereof;

wherein

Ar<sup>1</sup> and Ar<sup>2</sup> are independently phenyl or pyridyl,

Ar<sup>3</sup> is 1,4-arylene,

R<sup>1</sup> is selected from



X is O; and

Y is (C<sub>2</sub>-C<sub>3</sub>)alkylene.

12. (Amended) A compound as defined in Claim 1 selected from the group consisting of

